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Since the introduction of antiretroviral therapy (ART) for 
individuals who are HIV-infected with AIDS, there has been a 
dramatic decline in the number of these patients presenting with 
Pneumocystis jerovicii pneumonia (PcP) in the developed world. 
In South Africa, the antiretroviral (ARV) rollout was delayed for 
political reasons until 2004; consequently, significant numbers 
of patients are still presenting with PcP as a cause of respiratory 
failure. These patients are either unaware of their diagnosis or 
have not started ARVs for reasons that include poor access to 
medical facilities and drugs, denial and lack of education. If 
patients with PcP require mechanical ventilation, the prognosis 
is poor, with mortality ranging from 36 - 80%.1,2 In fact, prior 
to the availability of ARVs, such patients were not mechanically 
ventilated in South Africa as no definitive therapy was available. 
Once these agents became available to all HIV-positive patients 
with CD4 counts <200 cells/μl, it became feasible for them 
to be considered for ventilation. At the Charlotte Maxeke 
Johannesburg Academic Hospital, it soon became apparent that 
few of these patients survived, despite early initiation of both 
ART and effective chemotherapy for PcP. Management included 
use of ARDSNET low tidal volume strategies,3 conservative fluid 
protocols, adjunctive corticosteroids and minimal sedation. 
Despite these, mortality remained extremely high while other 
units were reporting 50 - 79% cure rates.1,4 It was consequently 
decided to prospectively investigate the patients who had died 
in the unit, with the aim of determining the causes of failure of 
therapy. Possibilities that had been considered for this failure 
were concurrent infections including cytomegalovirus,5,6 
Cryptococcus neoformans, mycobacterial or bacterial infections 
such as Streptococcus pneumonia, drug resistance, as well as 
pulmonary Kaposi’s sarcoma.7
Methods
This was a prospective study to investigate histological 
findings of patients who died from confirmed or suspected 
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Background. Pneumocystis pneumonia (PcP) is one of the 
most common opportunistic infections found in patients 
with HIV. The prognosis if ventilation is required is poor, 
with mortality of 36 - 80%. Although more recent studies 
have shown improved survival, our experience has been that 
close to 100% of such patients die, and we therefore decided 
to investigate further.
Methods. All patients with confirmed or suspected PcP 
who died owing to respiratory failure were eligible for the 
study. Where consent was obtained, trucut lung biopsies 
were performed post mortem, stored in formalin and sent 
for histopathological assessment.
Results. Twelve adequate lung biopsies were obtained 
from 1 July 2008 to 28 February 2011 – 3 from men and 
9 from women. The mean age was 34.7 years (range 
24 - 46), and the mean admission CD4 count was 20.8 
(range 1 - 68) cells/μl and median 18.5 cells/μl. All 
specimens demonstrated typical PcP histopathology; in 
addition, 9 showed significant interstitial fibrosis. Three had 
co-infection with cytomegalovirus (CMV), two of which 
had fibrosis present. There was no evidence of TB or other 
fungal infections.
Conclusion. The high mortality seen in this cohort 
of PcP patients was due to intractable respiratory failure 
from interstitial lung fibrosis. Whereas the differential 
includes ventilator induced lung injury, drug resistance 
or co-infections, we suggest that this is part of the disease 
progression in certain individuals. Further studies are 
required to identify interventions that could modify this 
process and improve outcomes in patients with PcP who 
require mechanical ventilation.
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PcP. All patients in these two categories, 
with respiratory failure, were considered 
for the study. PcP was suspected in patients 
with clinically advanced HIV presenting 
with hypoxic respiratory failure with typical 
chest radiograph changes, including bilateral 
diffuse alveolar infiltrates, granular opacities 
or, occasionally, unilateral or focal infiltrates.7 
Pneumocystis was confirmed ante mortem 
on sputum from 4 of the patients using the 
Giemsa stain; and 9 had organisms seen on 
histological samples. The remaining 3 had 
markedly elevated beta-D-glucan (BDG) 
levels >500 pg/ml.8 Pre-mortem biopsies or 
bronchial washings were not possible owing 
to the severity of the hypoxia. With family 
consent, multiple trucut biopsies were taken 
from different regions of the lungs of each 
patient after death. The specimens were stored 
in formalin and subsequently stained with 
Grocott, Gordon and Sweets, Alcian blue, 
Ziehl-Neelsen and haematoxylin and eosin. 
Ethics approval was given by the University of 
the Witwatersrand Ethics Committee.
Results
Sixteen lung biopsies were obtained from 
1 July 2008 to 28 February 2011. Table 1 
lists patient demographics and laboratory 
characteristics. Four were inadequate 
samples and therefore not included. The final 
12 were from 3 male and 9 female patients. 
Mean age of patients was 34.7 years (range 24 
- 46 years). Mean admission CD4 count 20.8 
(range 1 - 68) cells/μl, and the median CD4 
was 18.5 cells/μl.
ICU details
All 12 patients were admitted to the intensive 
care unit (ICU), where 10 were mechanically 
ventilated; none developed pneumothoraces. All 
received appropriate high-dose trimethoprim-
sulfamethoxazole (TMP-SMX) with high-dose 
corticosteroids as primary management. None 
were on ART at the time of presentation.
Histopathology
All 12 of the final specimens demonstrated 
the typical histopathological pattern of PcP, 
including alveoli filled with frothy material, 
type 2 cell hyperplasia and pneumocystis 
organisms. In addition, 9 of the 12 showed 
evidence of interstitial fibrosis with expansion 
of the interstitium by fibroblasts and collagen 
of varying degrees of severity. There was 
significant destruction and distortion of 
the lung architecture, resulting in a marked 
decrease in available alveolar-endothelial 
surface area for diffusion (Fig. 1). Three 
had evidence of CMV co-infection with 
intracellular inclusion bodies, and 2 of these 
also showed evidence of fibrosis. One of the 
latter 2 had a super-added bacterial infection 
that was not evident in any of the other 
specimens. There was no evidence of TB or 
other fungal infection in any of the specimens.
Discussion
Pneumocystis pneumonia is still one of the 
most common opportunistic infections found 
in patients infected with HIV.9 Pneumocystis 
is primarily an alveolar pathogen that 
does not invade the pneumocyte to which 
it tightly adheres. The histopathological 
changes that are seen are explained by the 
exuberant host inflammatory response to 
the organism, which promotes pulmonary 
injury in only some patients during infection. 
Severe pneumocystis pneumonia can result 
in a significant neutrophilic response that 
leads to diffuse alveolar damage, impaired 
gas exchange and respiratory failure.10 P. 
jirovecii has specific proteases that have the 
ability to damage the lung interstitium, and 
endogenous host proteases including matrix 
metalloproteinases (MMP) are also secreted 
in response to an influx of pro-inflammatory 
mediators (Interleukin-6 (IL-6), Interleukin-8 
(IL-8), monocyte chemotactic protein-1 
(MCP-1), and tumour necrosis factor alpha 
(TNF-α)) from alveolar epithelial cells.11,12 
This can explain the extensive capillary leak 
and frothy hyaline material that fills the 
alveolus in typical PcP. It is possible that 
the extensive effacement of normal alveolar 
architecture with fibrosis demonstrated in 
these biopsies is part of a reparative process 
that may occur only in those individuals 
genetically predisposed to the development 
of fibrosis, so that not all patients with PcP 
behave similarly.
In our sample, 75% of the patients who 
died of refractory respiratory failure revealed 
varying degrees of interstitial fibrosis resulting 
in obliteration of the alveolar capillary interface 
and loss of surface area for diffusion with 
the remainder, demonstrating unresponsive 
PcP. The pattern of the former is similar to 
that of the fibrotic stage of acute respiratory 
Table 1. Patient demographics and laboratory characteristics
Patient Sex Age (years)
CD4
cells/μl PcP on sputum
BDG
pg/ml PcP on histo CMV on histo Fibrosis
SM ♂ 27 11 N/A N/A Yes No Present
NM ♀ 46 19 Yes N/A Yes Yes None
MS ♂ 40 31 Yes 402 Yes No Present
DM ♀ 33 1 Yes >500 Yes Yes Present
NS* ♀ 44 29 Yes >500 No No Present
XD* ♀ 24 n.a. N/A >500 Yes No Present
NM ♀ 28 68 N/A >500 Yes No None
TR ♀ 24 22 N/A >500 Yes No Present
NM ♀ 25 7 N/A >500 No No Present
AM ♀ 46 18 N/A n.a. Yes No None
TM ♀ 41 n.a. N/A >500 No No Present
JN ♂ 38 2 N/A 51 Yes Yes Present
*Not ventilated.
N/A=not available.











distress syndrome (ARDS); and, whereas it 
might be argued that this could be consistent 
with ARDS following an infection by a more 
virulent organism such as Streptococcus 
pneumoniae, this organism was not cultured 
in vivo, and patients all received standard 
empiric therapy for community-acquired 
pneumonia. Importantly, none presented with 
the secondary organ dysfunction or systemic 
inflammatory response syndrome (SIRS), 
more typical of severe infections with this 
organism. In addition, all the patients received 
corticosteroids as a component of therapy for 
PcP that may be effective in the therapy of 
refractory ARDS owing to other causes.13
Another factor that could be responsible 
for the fibrotic injury is ventilator-induced 
lung injury (VILI). However, 2 of the 13 
patients were not ventilated, and their biopsies 
showed similar interstitial fibrotic changes 
to those who were, and the other 11 were 
ventilated with tidal volumes ≤6ml/kg, and 
were recruited and maintained on appropriate 
PEEP, making this explanation unlikely.
In South Africa, where medical resources 
are limited, the majority of patients with PcP 
and respiratory failure (most of whom have 
PaO2/FiO2 ratios <200) are treated with oxygen 
via a re-breathing mask and appropriate 
pharmacological therapy in the general wards. 
Only the most severely hypoxic patients or 
those who fail therapy are considered for 
ventilation. This observation highlights a 
weakness in our sample, with a selection bias 
for those with a worse prognosis. Patients 
who were not considered candidates for ICU 
admission might have developed respiratory 
failure and died in the general medical wards, 
or more usually might have made a full recovery 
despite initial low P/F ratios. The latter, who 
in more resource-rich environments would 
have been admitted to ICU, could account 
for the high survival rates in other studies. 
Those admitted to ICU in South Africa are 
preselected, with most having already received 
and failed appropriate pharmacotherapy. It has 
previously been reported in the pre-ART era 
that patients who required ventilation despite 
adequate and appropriate therapy, have a poor 
prognosis.4
The reasons for the failure of therapy and the 
failure to benefit from mechanical ventilation 
have not previously been well described. Why 
some patients and not others develop fibrosis 
has also not been adequately elucidated. It 
could be argued that these patients might have 
had 2 disease processes: PcP superimposed 
on a more chronic condition or that this 
was an acute exacerbation of a more chronic 
underlying inflammatory process similar to 
Fig. 1. Low magnification of alveoli showing normal interstitium of (a) alveolar walls and (b) alveolar spaces (Gordon and Sweet stain).
Fig. 2. High magnification showing an enlarged pneumocyte with (a) an intranuclear CMV inclusion (haemotoxylin and eosin stain).
Fig. 3. Low magnification showing (a) frothy exudate filling the alveolar spaces (haemotoxylin and eosin stain).
Fig. 4. Low magnification showing (a) marked expansion of the interstitium by fibrous tissue (Gordon and Sweet stain).











those that occur in the idiopathic interstitial 
pneumonias.14 However, this does not explain 
why these patients had elevated β-D glucan 
levels in the absence of fungal infection 
elsewhere, and X-ray features not compatible 
with the interstitial pneumonias; and in the 
latter case, why the histological features were 
typical of PcP. CMV has been postulated to 
be more than a ‘fellow traveller’ in patients 
with PcP, and treatment with gancyclovir has 
been reported to improve outcome.5,6 It is 
conceivable that infection by both organisms 
could be synergistic regarding the fibro-
proliferative effects. However, in only 3 
of our cohort was there evidence of CMV 
co-infection, 2 of whom did have fibrosis.
An important consideration for treatment 
failure is the possibility of resistance to sulfa 
drugs owing to mutations of Pneumocystis 
dihydropteroate synthase (DHPS) gene due to 
increased drug pressure from the widespread 
use of TMP-SMX prophylaxis. DHPS, the 
enzyme responsible for folate synthesis and 
the target of TMP-SMX, has undergone 
gene mutations that have been identified in 
56% of P. jirovecii strains in South Africa.15 
However, as human strains of PcP cannot 
be cultured in vitro, it is difficult to prove 
that these mutations confer drug resistance. 
A number of studies have evaluated the 
effect of these mutations on clinical outcomes 
with conflicting results. Helweg-Larsen et 
al. demonstrated that patients infected by 
organisms with a DHPS mutation had a 
threefold increased risk of death.16 Navin and 
colleagues, however, found no association 
with mortality at 6 weeks nor with treatment 
failure.17 In fact, they found that 85% of 
patients with DHPS mutations treated with 
TMP-SMX responded to treatment.
A limitation of our study is the small sample 
size. In view of our resource-limited setting, 
these patients are not often viewed as good 
ICU candidates. Therefore, even though the 
PCP burden in South African hospitals is 
high, the available ICU PcP population is 
restricted. We feel that these are important 
data and will add to the understanding of the 
clinical course of these patients, even taking 
into account the small sample size.
Interstitial fibrosis has previously been 
demonstrated in patients who have survived 
an episode of PcP, as well as on previous 
necropsy studies.4,18 There have also been 
histological reports of cryptogenic organising 
pneumonia, granulomatous inflammation and 
diffuse alveolar damage.19 Our cohort, however, 
was unusual in that the majority of patients 
with PcP, most of whom were ventilated, had 
evidence of extensive pulmonary fibrosis 
– which was associated with an extremely 
poor prognosis. This phenomenon has been 
described previously; however, it has not been 
highlighted as the probable underlying cause 
for treatment failure and death. We suggest 
that, if we want to improve the dismal outcome 
of these patients, we need to consider the 
state of the underlying lung, and realise that 
treatment of the organism alone is insufficient. 
Primarily, we need to expand the rollout of 
ARVs and, failing this, try to both recognise 
and treat the condition sooner, prior to the 
development of fibrosis. Ideally, we should also 
develop a management protocol that addresses 
the lung fibrosis once it has occurred.
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